Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Arcus Biosciences Inc’s stock clocked out at $15.26, down -1.93% from its previous closing price of $15.56. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 0.5 million shares were traded. RCUS stock price reached its highest trading level at $15.56 during the session, while it also had its lowest trading level at $15.03.
Ratios:
To gain a deeper understanding of RCUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.
On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’24 when Jarrett Jennifer sold 11,551 shares for $17.55 per share. The transaction valued at 202,720 led to the insider holds 215,253 shares of the business.
Jarrett Jennifer sold 13,449 shares of RCUS for $240,941 on Mar 18 ’24. The Chief Operating Officer now owns 226,804 shares after completing the transaction at $17.92 per share. On Feb 27 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 34,070 shares for $20.11 each. As a result, the insider received 685,148 and left with 240,253 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1387939712 and an Enterprise Value of 775856768. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.86 while its Price-to-Book (P/B) ratio in mrq is 2.49. Its current Enterprise Value per Revenue stands at 6.631 whereas that against EBITDA is -2.337.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $25.47, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is -10.80%, while the 200-Day Moving Average is calculated to be -11.95%.
Shares Statistics:
It appears that RCUS traded 756.83K shares on average per day over the past three months and 495760 shares per day over the past ten days. A total of 75.50M shares are outstanding, with a floating share count of 47.38M. Insiders hold about 47.91% of the company’s shares, while institutions hold 54.23% stake in the company. Shares short for RCUS as of 1713139200 were 6842934 with a Short Ratio of 9.04, compared to 1710460800 on 7983992. Therefore, it implies a Short% of Shares Outstanding of 6842934 and a Short% of Float of 15.619999000000002.
